Adverum Biotechnologies (ADVM) Reaching An Inflection Point; Piper Jaffray Initiates Shares At “Buy” with $12.0000 target

May 18, 2018 - By Marguerite Chambers

Why Has Piper Jaffray Given Adverum Biotechnologies (ADVM) a $12.0000 Price Target

Piper Jaffray analyst has begun coverage with a “Buy” rating on Adverum Biotechnologies (ADVM) today and set a price target of $12.0000. The firm’s shares opened today at 6.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Ratings Coverage

Among 2 analysts covering Adverum Biotechnologies (ADVM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adverum Biotechnologies had 2 analyst reports since January 4, 2018 according to SRatingsIntel. The stock of Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has “Buy” rating given on Thursday, February 15 by Piper Jaffray.

The stock decreased 2.44% or $0.15 during the last trading session, reaching $6. About 544,114 shares traded. Adverum Biotechnologies, Inc. (ADVM) has risen 103.64% since May 18, 2017 and is uptrending. It has outperformed by 92.09% the S&P500.

Analysts await Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to report earnings on August, 14. They expect $-0.30 earnings per share, down 11.11 % or $0.03 from last year’s $-0.27 per share. After $-0.30 actual earnings per share reported by Adverum Biotechnologies, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has market cap of $373.63 million. The firm has a pipeline that includes product candidates to treat wet age-related macular degeneration , alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. It currently has negative earnings. The Company’s lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT.

More notable recent Adverum Biotechnologies, Inc. (NASDAQ:ADVM) news were published by: Nasdaq.com which released: “Adverum Biotechnologies Announces Long-term Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMD” on May 01, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: AstraZeneca’s Q1, Novartis-Amgen Migraine Drug Approved” published on May 18, 2018, Nasdaq.com published: “Adverum Biotechnologies Presents Additional Long-term Preclinical Data on ADVM-022 in Wet AMD at ASGCT 21st …” on May 18, 2018. More interesting news about Adverum Biotechnologies, Inc. (NASDAQ:ADVM) were released by: 247Wallst.com and their article: “Top Analyst Upgrades and Downgrades: Aimmune, Anadarko, Carrizo, Mastercard, PayPal, Spotify, Visa and More” published on May 18, 2018 as well as Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: May 18, 2018.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.